Multiple Sclerosis Clinical Trial
Official title:
Investigating Baseline Cortical Haemodynamics in Multiple Sclerosis
This study will provide information on cortical haemodynamics in MS patients to address the discrepancies reported in previous literature, allowing further insight into the role of haemodynamics in the disease. It will also instruct us as to the most effective scanning protocols for future research. Developing a suitable protocol for studying perfusion longitudinally may also enable identification of new therapeutic interventions to normalise any perfusion abnormalities in MS patients.
We aim to characterise the underlying cortical haemodynamics in Multiple Sclerosis (MS). We
will assess two techniques for measuring blood flow in the brain: arterial spin labelling
(ASL) and dynamic susceptibility contrast (DSC) magnetic resonance imaging in the MS patient
group. ASL is a non-invasive technique whilst DSC-MR requires the administration of a tracer
intravenously. Previous studies have shown conflicting results from these measurements.
Reproducibility of ASL and disease activity will also be assessed through repeated scan
sessions. Global perfusion in the MS patient group will be compared to a matched healthy
control group.
In addition to measuring blood flow using both methods, we will investigate whether
differences in perfusion between the MS patient group and the healthy controls can be
observed using ASL, and also assess the reproducibility of ASL measurements via repeated
scans. These repeated scanning sessions also provide a window to study disease activity in
the patient cohort, and patients may be invited to return for up to a total of 4 scanning
sessions (with only one involving the use of DSC) to better assess the usefulness of ASL in
tracking haemodynamic changes in MS.
Study Regimen:
We aim to recruit 20 MS patients and 20 healthy age-matched controls for this study.
MS Patient Cohort:
The patients will be asked to attend two initial scanning sessions. MS Scan Session 1 will
involve the use of the Prohance contrast agent, taking of blood samples and an MRI scan. MS
Scan Session 2 will only involve the use of a non-invasive MRI scan.
MS Scan Session 1:
This session will require the administration of a gadolinium contrast agent. Prior to
entering the scanner, a cannula is inserted into the patient's arm (cannula A). A small blood
sample (5ml) will be taken from all MS patients in order to assess the haematocrit and
creatinine content which will be used to determine if they are eligible for gadolinium
administration (via use of the POCT i-Stat). This will provide a measure of eGFR which will
provide information on the patient's renal function. This will only be performed once per
patient and results will be recorded in the CRF. Provided the patient's eGFR is adequate for
the study, a second cannula will be inserted into the patient's other arm (cannula B). The
patient will enter the scanner with lines attached to both cannulae. The gadolinium bolus
will be administered by a clinician in the scan room between scans via cannula A*. During the
remainder of the visit, three subsequent blood samples will be taken (up to 5ml each), via
cannula B, which will be used to measure gadolinium concentration. Gadolinium administration
and blood work will be performed by physicians who are part of the research team with ALS
training.
* Gadolinium contrast agents allow for the accurate quantification of blood flow from MR
imaging. Prohance (Gadoteridol) is a gadolinium-based fluid administered intravenously to the
participant. The contrast agent will be administered by physician with advanced life support
(ALS) training. The physician will remain present throughout the duration of the scan and at
all times whilst the participant is present at the Sir Peter Mansfield Imaging Centre. In the
event of an emergency, a resuscitation kit is readily available. Also, the University's
internal emergency phone number is contacted to readily direct emergency services to the
site.
MS Scan Session 2:
The patients will be asked to return for MS Scan Session 2 two weeks after completing MS Scan
Session 1. Before each scanning session, the patient will be asked to complete and MR safety
questionnaire to ensure that no contraindications have arisen between scans. Explanations of
what to expect in the MRI scanner environment will be given prior to being asked to sign a
consent form. Provided there are no contraindications for the volunteer to enter the scanner,
the volunteer will undergo a non-invasive MRI scan lasting approximately 1 hour. No other
interventions are to be used. All scanning will be performed using a 7 Tesla Philips Achieva
scanner with multi-transit capability (Philips Medical Systems, Best, The Netherlands). The
participants will be scanned with a 32-channel receive coil. The subjects will wear-ear
plugs, ear defenders and a pulse oximeter (to monitor the pulse) throughout contrast agent
administration.
After the completion of MS Scan Sessions 1 and 2, their scans will be analysed and
interpreted by a member of the patient's clinical care team. If a patient presents any
morphological changes relating to the disease between MS Scan Sessions 1 and 2, the patient
will be invited back for an additional 2 scans, labelled as MS Scan Session 3 and 4. If there
is no presentation of additional lesions between scans, this will be the end of the patient's
participation.
MS Scan Sessions 3 and 4:
These will be identical to MS Scan Session 2 (non-invasive MRI scan only). MS Scan Session 3
will take place at 6 weeks and MS Scan Session 4 will take place at 12 weeks.
Healthy Volunteers:
The healthy volunteers will be asked to attend two scanning sessions (labelled as HV Scan
Session 1 and HV Scan Session 2 in the flow chart). Both HV Scan Session 1 and 2 will only
involve the use of a non-invasive MRI scan. No gadolinium contrast agent is to be given to
the healthy volunteers during this study.
Both HV Scan Session 1 and 2 will be identical to MS Scan Sessions 2, 3 and 4. Upon
completing HV Scan Session 1, the healthy volunteer will be invited back for HV Scan Session
2 two weeks later. After completing HV Scan Session 2, the healthy volunteer's participation
will be finished.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT02845635 -
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
|